BASF Venture Capital (BVC) has invested in Bota Biosciences (Bota Bio), an industrial synthetic biotech company based in Hangzhou, China. Bota Bio, founded in 2019, is developing a proprietary next-generation biotechnology platform which enables sustainable and economical production of high value products for a broad array of industrial applications. Examples are sweeteners, vitamins, personal care or crop protection products.

Computation is the core and foundation of Bota Bio’s next-generation bio-foundry to build and evolve enzyme, strain and process pipelines. It quickly identifies and characterizes suitable microbial hosts, shuffles and combines desired phenotypes to create new industrial strains, and furthermore develops and improves manufacturing processes starting from green raw materials, such as sugar.

Bota Bio’s interdisciplinary team – including biologists, chemists, engineers and industry veterans – has a strong track record in successful development and commercialization of products and plans to continue bringing valuable and innovative products to the market. Bota Bio’s innovative fermentation process is scalable making commercial production possible.

“The founding members of Bota Bio have a wealth of experience in the fields of biotechnology and chemistry as well as in starting companies,” said Markus Solibieda, BVC’s Managing Director. He added: “Bota Bio’s highly innovative platform enables the acceleration of product development and contributes to sustainable and economical production. It has the potential to shape progress for the future of the chemical industry. With our investment in this promising young company, we are strengthening BASF’s activities related to sustainability and enhancing the group’s potential for innovation in the dynamic Asian markets.” 

Bota Bio will use this investment to expand its development and production capabilities. “In BASF, we have a strong industry partner by our side whose strengths optimally complement our own. We welcome this support in scaling up our processes and launching new products,” said Cheryl Cui, Ph.D., CEO of Bota Bio.